CU20150058A7 - Derivados de imidazopiridazina como receptores de moduladores gabaa - Google Patents

Derivados de imidazopiridazina como receptores de moduladores gabaa

Info

Publication number
CU20150058A7
CU20150058A7 CUP2015000058A CU20150058A CU20150058A7 CU 20150058 A7 CU20150058 A7 CU 20150058A7 CU P2015000058 A CUP2015000058 A CU P2015000058A CU 20150058 A CU20150058 A CU 20150058A CU 20150058 A7 CU20150058 A7 CU 20150058A7
Authority
CU
Cuba
Prior art keywords
derivatives
imidazopiridazine
receivers
present
gabaa
Prior art date
Application number
CUP2015000058A
Other languages
English (en)
Other versions
CU24338B1 (es
Inventor
Kiyoyuki Omoto
Robert Mckenzie Owen
David Cameron Pryde
Christine Anne Louise Watson
Mifune Takeuchi
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of CU20150058A7 publication Critical patent/CU20150058A7/es
Publication of CU24338B1 publication Critical patent/CU24338B1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a derivados de imidazopiridazina. Más en particular, se refiere a derivados de 4-(bifenil-3-il)-7H-imidazo[4,5-c]piridazina de la Fórmula (I): ESPACIO PARA FÓRMULA y a sales de estos aceptables desde el punto de vista farmacéutico, en donde R1, R2, R3, R4 y R5 son como se definieron en la descripción. Los derivados de imidazopiridazina de la presente invención modulan la actividad del receptor GABAA. Son útiles para el tratamiento de diversas afecciones, por ejemplo, el dolor. La presente invención también se refiere a una composición química de derivados de imidazopiridazina, útiles para el tratamiento de diversas afecciones, por ejemplo, el dolor.
CUP2015000058A 2012-12-14 2013-12-04 Derivados de imidazopiridazina como receptores de moduladores gabaa CU24338B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261737157P 2012-12-14 2012-12-14
PCT/IB2013/060631 WO2014091368A1 (en) 2012-12-14 2013-12-04 Imidazopyridazine derivatives as gabaa receptor modulators

Publications (2)

Publication Number Publication Date
CU20150058A7 true CU20150058A7 (es) 2015-11-27
CU24338B1 CU24338B1 (es) 2018-04-03

Family

ID=49880883

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2015000058A CU24338B1 (es) 2012-12-14 2013-12-04 Derivados de imidazopiridazina como receptores de moduladores gabaa

Country Status (44)

Country Link
US (3) US8952008B2 (es)
EP (1) EP2938615B1 (es)
JP (1) JP5869740B2 (es)
KR (1) KR101746314B1 (es)
CN (1) CN104837843B (es)
AP (1) AP2015008526A0 (es)
AR (1) AR093937A1 (es)
AU (1) AU2013356894B2 (es)
BR (1) BR112015014097B1 (es)
CA (1) CA2892174C (es)
CL (1) CL2015001652A1 (es)
CR (1) CR20150254A (es)
CU (1) CU24338B1 (es)
CY (1) CY1118568T1 (es)
DK (1) DK2938615T3 (es)
DO (1) DOP2015000147A (es)
EA (1) EA025635B1 (es)
EC (1) ECSP15029822A (es)
ES (1) ES2608640T3 (es)
GE (1) GEP201706710B (es)
GT (1) GT201500159A (es)
HK (1) HK1209743A1 (es)
HR (1) HRP20161559T1 (es)
HU (1) HUE032400T2 (es)
IL (1) IL239243A0 (es)
LT (1) LT2938615T (es)
MA (1) MA38112B1 (es)
MD (1) MD4651B1 (es)
ME (1) ME02566B (es)
MX (1) MX366023B (es)
NI (1) NI201500081A (es)
PE (1) PE20151163A1 (es)
PH (1) PH12015501293B1 (es)
PL (1) PL2938615T3 (es)
PT (1) PT2938615T (es)
RS (1) RS55307B1 (es)
SG (1) SG11201503735YA (es)
SI (1) SI2938615T1 (es)
TN (1) TN2015000261A1 (es)
TW (1) TWI478926B (es)
UA (1) UA112028C2 (es)
UY (1) UY35185A (es)
WO (1) WO2014091368A1 (es)
ZA (1) ZA201504226B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6491679B2 (ja) * 2014-06-12 2019-03-27 ファイザー・リミテッドPfizer Limited Gabaa受容体活性のモジュレーターとしてのイミダゾピリダジン誘導体
MX2017001462A (es) 2014-07-31 2017-05-23 Basf Se Proceso para la preparacion de pirazoles.
PE20180327A1 (es) 2015-05-11 2018-02-13 Basf Se Proceso para preparar 4-amino-piridazinas
JP2018536677A (ja) * 2015-12-10 2018-12-13 ファイザー・リミテッドPfizer Limited てんかんおよび疼痛の治療において使用するための、GABA受容体モジュレーターとしての式(I)の4−(ビフェン−3−イル)−1H−ピラゾロ[3,4−c]ピリダジン誘導体
LT3515894T (lt) * 2016-09-23 2021-07-26 Novartis Ag Indazolo junginiai, skirti vartoti sausgyslių ir (arba) raiščių pažeidimų atvejais
JOP20190053A1 (ar) * 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
WO2018082964A1 (en) 2016-11-04 2018-05-11 Basf Se Process for the production of pyridazinyl-amides in a one-pot synthesis
WO2018202494A1 (de) 2017-05-02 2018-11-08 Bayer Aktiengesellschaft 2-(het)aryl-substituierte kondensierte heterocyclen-derivate als schädlingsbekämpfungsmittel
AU2018282104A1 (en) * 2017-06-06 2019-12-12 Urovant Sciences Gmbh Use of vibegron to treat overactive bladder
EP3796907A4 (en) * 2018-05-22 2021-11-03 Neurocycle Therapeutics, Inc. GABAA POSITIVE ALLOSTERIC MODULATING COMPOUNDS FOR THE TREATMENT OF PRURITUS AND / OR DERMATITIS
TW202214648A (zh) * 2019-01-07 2022-04-16 美商美國禮來大藥廠 Il-17a抑制劑
CN116693555A (zh) * 2022-02-25 2023-09-05 上海赛默罗生物科技有限公司 咪唑并哒嗪类衍生物、其制备方法、药物组合物和用途
CN117069725A (zh) * 2022-05-10 2023-11-17 上海赛默罗生物科技有限公司 咪唑并哒嗪取代苯环类衍生物、制备方法、药物组合物及用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
GB0117277D0 (en) 2001-07-16 2001-09-05 Merck Sharp & Dohme Therapeutic agents
US6936608B2 (en) 2000-11-10 2005-08-30 Merck Sharp & Dohme Ltd. Imidazo-triazine derivatives as ligands for GABA receptors
WO2005080355A1 (en) * 2004-02-12 2005-09-01 Neurogen Corporation Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands
US20080132510A1 (en) 2005-01-21 2008-06-05 Bingsong Han Imidazolylmethyl and Pyrazolylmethyl Heteroaryl Derivatives
EP1845098A1 (en) * 2006-03-29 2007-10-17 Ferrer Internacional, S.A. Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands
ATE461177T1 (de) 2007-03-23 2010-04-15 Icagen Inc Ionenkanal-hemmer
JP5053459B2 (ja) 2009-01-12 2012-10-17 アイカジェン, インコーポレイテッド スルホンアミド誘導体
ES2651296T3 (es) * 2009-10-30 2018-01-25 Janssen Pharmaceutica, N.V. Derivados de imidazo[1,2-b]piridacina y su uso como inhibidores de PDE10
US9096558B2 (en) * 2010-07-09 2015-08-04 Pfizer Limited N-sulfonylbenzamide compounds

Also Published As

Publication number Publication date
AU2013356894B2 (en) 2015-11-12
LT2938615T (lt) 2016-12-27
CR20150254A (es) 2015-07-09
ES2608640T3 (es) 2017-04-12
CN104837843A (zh) 2015-08-12
US20150105396A1 (en) 2015-04-16
HK1209743A1 (zh) 2016-04-08
US20140171435A1 (en) 2014-06-19
US8952008B2 (en) 2015-02-10
RS55307B1 (sr) 2017-03-31
PH12015501293A1 (en) 2015-08-24
EP2938615A1 (en) 2015-11-04
JP5869740B2 (ja) 2016-02-24
AU2013356894A1 (en) 2015-05-28
BR112015014097A2 (pt) 2019-12-17
DK2938615T3 (da) 2017-01-02
US20150259352A1 (en) 2015-09-17
EA025635B1 (ru) 2017-01-30
SI2938615T1 (sl) 2017-02-28
GT201500159A (es) 2015-09-23
JP2016503001A (ja) 2016-02-01
MD4651B1 (ro) 2019-09-30
AP2015008526A0 (en) 2015-06-30
HUE032400T2 (hu) 2017-09-28
EA201590761A1 (ru) 2015-12-30
PH12015501293B1 (en) 2015-08-24
ECSP15029822A (es) 2017-08-31
TN2015000261A1 (fr) 2016-10-03
CN104837843B (zh) 2016-08-31
IL239243A0 (en) 2015-07-30
DOP2015000147A (es) 2015-09-15
GEP201706710B (en) 2017-07-25
UA112028C2 (uk) 2016-07-11
CY1118568T1 (el) 2017-07-12
SG11201503735YA (en) 2015-07-30
KR101746314B1 (ko) 2017-06-12
NI201500081A (es) 2015-09-16
UY35185A (es) 2014-07-31
PT2938615T (pt) 2016-12-26
TW201434840A (zh) 2014-09-16
CU24338B1 (es) 2018-04-03
HRP20161559T1 (hr) 2016-12-30
CA2892174C (en) 2018-02-06
KR20150088877A (ko) 2015-08-03
EP2938615B1 (en) 2016-10-26
MA38112A1 (fr) 2018-03-30
CL2015001652A1 (es) 2015-08-14
MD20150051A2 (ro) 2015-09-30
MX2015007598A (es) 2015-10-22
WO2014091368A1 (en) 2014-06-19
ME02566B (me) 2017-02-20
ZA201504226B (en) 2016-06-29
BR112015014097B1 (pt) 2022-11-29
TWI478926B (zh) 2015-04-01
MX366023B (es) 2019-06-24
CA2892174A1 (en) 2014-06-19
AR093937A1 (es) 2015-07-01
PE20151163A1 (es) 2015-08-14
MA38112B1 (fr) 2018-10-31
PL2938615T3 (pl) 2017-04-28

Similar Documents

Publication Publication Date Title
CU20150058A7 (es) Derivados de imidazopiridazina como receptores de moduladores gabaa
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
CL2017001050A1 (es) Nuevos compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2
DOP2015000241A (es) Compuestos de biaril-amida como inhibidores de cinasa
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
ECSP14013215A (es) Compuestos novedosos
NI201400107A (es) Compuestos de heterociclilo como inhibidores de mek
ECSP15025947A (es) Derivados de cloro-pirazin carboxamida con actividad bloqueadora sobre los canales de sodio epiteliales
UY35012A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
ECSP13012448A (es) Nuevas aminopirazoloquinazolinas.
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
CR20110610A (es) Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
CR20150171A (es) Benzamidas
ECSP13012596A (es) Proceso de elaboración para derivados de pirimidina
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
ECSP16074478A (es) Compuestos novedosos
CR20150378A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
CL2015003195A1 (es) Derivados de purina como agonistas del receptor cb2.
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
ECSP17069696A (es) Compuestos novedosos
CL2015003196A1 (es) Derivados de pirrolo[2,3-d]pirimidina como agonistas del receptor cb2.